Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by wasagastaron Aug 03, 2017 1:15pm

104 Views

Post# 26543752

RE:RE:RE:RE:RE:RE:RE:RE:RE:Phase 2

2b7f6fab wrote: If tlt1433 goes 100% or nearly so for 3 @ 6 months, and 6 more @ 3 months, I would imagine the Urologic community would put a lot of pressure on HC/FDA to approve a hurry up PH2. Or just expand Ph1 to add 20 more patients at PM/UHN and 20 at MD Anderson. Then tabulate 3 months results, if efficacy is showing then halt the trial and approve the drug/process on the spot. or in less than a year from now.

That is called practical thinking, nice post. When everything is clear and simple and safe and effective, you go with it. I hope they have such clear thinking when considering the data.

Bullboard Posts

Quest Diagnostics to acquire LifeLabs from OMERS for C$1.35 billion